Jeremy Kratz, MD
Hematology & Oncology · Madison, WINPI 1417344177
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,015 of the $8,702 with a category attached, or 69.1%. Boehringer Ingelheim International GmbH accounts for 78.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $7,665 and has fallen 90.3% since, to $740 in 2025.
Across 8 payments — averaging $1087.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$7K
- AstraZeneca$2K
- Trisalus Life Sciences, Inc.$171
- Genentech USA, Inc.$125
Across 199 payments — averaging $7857.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$683K
- Astellas Pharma Inc$534K
- Genentech, Inc.$226K
- Coherus Oncology, Inc.$82K
- Janssen Research & Development, LLC$32K
- Boehringer Ingelheim Pharma GmbH & Co.kg$6K
- plus $1K from 1 others
What the payments were for
- Consulting fees$6,01569%
- Speaking & faculty fees$2,39027%
- Food & beverage$2973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 3 | $6,830 |
| AstraZeneca | 3 | $1,575 |
| Trisalus Life Sciences, Inc. | 1 | $171 |
| Genentech USA, Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,050
- LYNPARZA$525
- TRINAV INFUSION SYSTEM$171
- Avastin$125
How this compares
$8,702 in reported general payments places this provider in the 75th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $13,207 |
| Dexamethasone | 38 | $699 |
| Oxycodone Hcl | 20 | $318 |
| Ondansetron Hcl | 43 | $300 |
| Prochlorperazine Maleate | 26 | $300 |
| Pantoprazole Sodium | 12 | $115 |
| Olanzapine | 18 | $69 |
| Levothyroxine Sodium | 11 | $41 |
| Furosemide | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Madison
- Vincent MaMadison$37K
- Priyanka PophaliMadison$32K
- Hamid EmamekhooMadison$23K
- Elisavet PaplomataMadison$21K
- Timothy SchmidtMadison$19K
- Sima Ehsani ChimehMadison$17K
- Kalyan Vara Ganesh NadimintiMadison$17K
- Christos KyriakopoulosMadison$16K
- Matthew BrunnerMadison$15K
- Lyndsey RunaasMadison$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.